---

Synthesis, crystal structure studies, characterization and study of novel heterocyclic thiadiazoles as caspase 3 inhibitors for anticancer activity

Full Text PDF

---

Original Article

Author Details : Bhavini K Gharia*, Bhanubhai N Suhagia, Vineet Jain

Volume : 10, Issue : 4, Year : 2023

Article Page : 268-275

https://doi.org/10.18231/j.ijpca.2023.045

Suggest article by email

Get Permission

Abstract

In the present study we have reported the synthesis of some novel heterocyclic derivatives comprising imidazole and 1,3,4-thiadiazole containing cyclopropyl moiety. Imidazothiadiazoles are of interest because of their diverse biological activities and clinical applications. Primarily docking studies are carried out with reference structure Pdb code:2DKO. We have reported the new series of 5,6 diaryl substituted with imidazo[2,1- b], , thiadiazoles analogs to target caspase family cysteine proteases. The reaction was monitored by Thin-layer chromatography using suitable mobile phase. The Rf values were compared and determined the melting point of synthesized compounds. Further these derivatives were characterized and confirmed by IR, 1H-NMR, 13C-NMR, and Mass spectral (MS) studies. For anticancer activity, all the selected compounds submitted to National Cancer Institute (NCI) for in vitro anticancer assay were evaluated for their anticancer activity. Primary one dose anticancer assay was performed in full NCI 60 cell panel in accordance with the protocol of the NCI, USA. The compounds and showed good activity against all cancer cell lines. The synthesized drugs were monitored with Caspase 3 inhibitor kit.(CASP3C-1KT)using colorimeteric assay.

Keywords: Anticancer drugs, Caspase family steine proteases, Colorimeteric Caspase 3 inhibitor kit

How to cite : Gharia B K, Suhagia B N, Jain V, Synthesis, crystal structure studies, characterization and study of novel heterocyclic thiadiazoles as caspase 3 inhibitors for anticancer activity. Int J Pharm Chem Anal 2023;10(4):268-275

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.